Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.

Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis / S. Villani, N. Zanotta, F. Ambrogi, M. Comar, D. Franciotta, M. Dolci, C. Cason, R. Ticozzi, P. Ferrante, S. Delbue. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 310(2017 Sep 15), pp. 91-96.

Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis

Villani, Sonia;Ambrogi, Federico;Dolci, Maria;Ticozzi, Rosalia;Ferrante, Pasquale;Delbue, Serena
2017-09-15

Abstract

Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.
Cytokines; JC virus; Natalizumab; Adult; Antibodies, Viral; Cytokines; Female; Follow-Up Studies; Humans; Immunologic Factors; Intercellular Signaling Peptides and Proteins; JC Virus; Male; Multiple Sclerosis; Natalizumab; T-Lymphocyte Subsets; Time Factors; Immunology and Allergy; Immunology; Neurology; Neurology (clinical)
Settore MED/07 - Microbiologia e Microbiologia Clinica
Tecnologie OMICS e Systems Biology per la definizione di nuove strategie finalizzate al controllo delle infezioni virali
JOURNAL OF NEUROIMMUNOLOGY
Article (author)
File in questo prodotto:
File Dimensione Formato  
ms_and_cytokine_preprint.pdf

accesso aperto

147.38 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/551541
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact